4-acetylamino-1-methyl-2(1H)-pyrimidinone | 7329-75-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-acetylamino-1-methyl-2(1H)-pyrimidinone
• 英文别名: N³-Methyl-N⁶-acetyl-cytosin；4-Acetamino-1-methyl-2-oxo-pyrimidin, N⁴-Acetyl-1-methyl-cytosin；4-acetylamino-1-methyl-1H-pyrimidin-2-one；N-(1-methyl-2-oxo-1,2-dihydro-pyrimidin-4-yl)-acetamide；N-(1-Methyl-2-oxo-1,2-dihydro-pyrimidin-4-yl)-acetamid；N-(1-methyl-2-oxopyrimidin-4-yl)acetamide
• CAS: 7329-75-1
• 化学式: C₇H₉N₃O₂
• 分子量: 167.167
• InChiKey: UHMXDXYQTAXVMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  61.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 4-acetylamino-1-methyl-2(1H)-pyrimidinone 生成 N⁴-Acetyl-1,3-dimethylcytosin
  参考文献：
  名称：

  Kenner et al., Journal of the Chemical Society, 1955, p. 855,859

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲氧基-1-甲基嘧啶-2-酮 在 吡啶 、 甲醇 、 氨 作用下， 生成 4-acetylamino-1-methyl-2(1H)-pyrimidinone
  参考文献：
  名称：

  Kenner et al., Journal of the Chemical Society, 1955, p. 855,859

  摘要：

  DOI：

文献信息

• [EN] TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION<br/>[FR] TECHNOLOGIES UTILES POUR LA PRÉPARATION D'OLIGONUCLÉOTIDES
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2020191252A1

  公开（公告）日：2020-09-24

  Among other things, the present disclosure provides technologies for oligonucleotide preparation, particularly chirally controlled oligonucleotide preparation, which technologies provide greatly improved crude purity and yield, and significantly reduce manufacturing costs.

  除其他事项外，本公开提供了寡核苷酸制备技术，特别是手性控制的寡核苷酸制备技术，这些技术大大提高了粗品纯度和产量，并显著降低了制造成本。
• [EN] 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF<br/>[FR] ACIDES NUCLÉIQUES PHOSPHONATE DE 4'-O-MÉTHYLÈNE ET ANALOGUES DE CEUX-CI
  申请人：DICERNA PHARMACEUTICALS INC

  公开号：WO2021146488A1

  公开（公告）日：2021-07-22

  The present invention relates to nucleic acids and analogues thereof useful as potent and stable RNA interference agents.

  本发明涉及用作有效和稳定的RNA干扰剂的核酸及其类似物。
• 2-FLUORINATED RIBOSES AND ARABINOSES AND METHODS OF USE AND SYNTHESIS
  申请人：Sauve Anthony A.

  公开号：US20120108535A1

  公开（公告）日：2012-05-03

  Disclosed are halogenated 2-deoxy-lactone, 2′-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, and a method of treating a disorder is selected from the group consisting of an abnormal cellular proliferation, a viral infection, and an autoimmune disorder.

  本发明涉及卤代的2-去氧内酯，2'-去氧核苷以及它们的衍生物，例如，化合物式（I）的化合物。本发明还涉及一种包含药学上可接受的载体和至少一种本发明化合物或盐的组合物，以及一种治疗异常细胞增殖、病毒感染和自身免疫性疾病等疾病的方法。
• [EN] OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSITIONS D'OLIGONUCLÉOTIDES ET PROCÉDÉS ASSOCIÉS
  申请人：WAVE LIFE SCIENCES LTD

  公开号：WO2022099159A1

  公开（公告）日：2022-05-12

  Among other things, the present disclosure provides oligonucleotides and compositions thereof. In some embodiments, provided oligonucleotides and compositions are useful for adenosine modification. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine modification.

  除其他事项外，本公开提供寡核苷酸及其组合物。在某些实施例中，提供的寡核苷酸及其组合物对腺苷修饰有用。在某些实施例中，本公开提供了治疗各种需要腺苷修饰的疾病、疾病或病症的方法。
• HSAB-driven chemoselective N1-alkylation of pyrimidine bases and their 4-methoxy- or 4-acetylamino-derivatives
  作者：Augusto Gambacorta、Daniela Tofani、Maria Antonietta Loreto、Tecla Gasperi、Roberta Bernini

  DOI：10.1016/j.tet.2006.04.098

  日期：2006.7

  The lithium salts of the conjugated bases of 4-methoxy- and 4-acetylamino-2(1H)-pyrimidinones 1-3 undergo highly chemoselective N-1-methylation or ethylation when treated with methyl- or ethylsulfate (hard electrophiles) in dry dioxane, while the use of DMF as solvent results in competitive O-2-alkylation. Potassium salts of the same bases in DMF undergo prevalent O-2-attack. Under the same conditions, a similar but less chemoselective behaviour is observed in alkylation of thymine and uracil, where some N-3 -attack occurs. This can be rationalised in terms of the HSAB principle. (c) 2006 Elsevier Ltd. All rights reserved.

表征谱图